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http://www.biomedcentral.com/1471-2407/12/487RESEARCH ARTICLE Open AccessStatin use and association with colorectal cancer
survival and risk: case control study with
prescription data linkage
Fatim Lakha1*, Evropi Theodoratou1, Susan M Farrington2, Albert Tenesa2, Roseanne Cetnarskyj3, Farhat V N Din2,
Mary E Porteous4, Malcolm G Dunlop2 and Harry Campbell1,2Abstract
Background: In Scotland colorectal cancer (CRC) is the third most common cancer and a leading cause of cancer
death. Epidemiological studies have reported conflicting associations between statins and CRC risk and there is one
published report of the association between statins and CRC survival.
Methods: Analysis was carried out on 309 cases and 294 controls from the Scottish Study of Colorectal Cancer
(SOCCS). Cox’s hazard and logistic regression models were applied to investigate the association between statin use
and CRC risk and survival.
Results: In an adjusted logistic regression model, statins were found to show a statistically significant association
for three of the four statin variables and were found to not show a statistically significant association with either
all-cause or CRC-specific mortality (OR 0.49; 95%CI 0.49-1.36; p-value = 0.17 and OR 0.33; 95%CI 0.08-1.35; P-value =
0.12, respectively).
Conclusion: We did find a statistically significant association between statin intake and CRC risk but not statin
intake and CRC-specific mortality. However, the study was insufficiently powered and larger scale studies may be
advisable.Background
Scotland has one of the highest incidences of colorectal
cancer in the world. Colorectal cancer (CRC) is the third
most commonly diagnosed cancer in both men and
women (15% of cancer cases in men; 11.6% of cancer
cases in women). Approximately 3,900 new cases are
diagnosed each year and 95% of cases occur in people
aged over 50 years. Over recent years both the incidence
and mortality rates have fallen for both sexes. However,
CRC remains the second most common cause of cancer
deaths for men (10.1% of cancer-related deaths) and the
third for women (9.6% of cancer related deaths) with ap-
proximately 1500 people dying of the disease in Scotland
each year [1].
The main risk factors, excluding genetic, for colorectal
cancer are dietary, obesity, lack of physical activity and* Correspondence: fatim.lakha@nhs.net
1Centre for Population Health Sciences, University of Edinburgh, Teviot Place,
Edinburgh EH8 9AG, UK
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reproduction in any medium, provided the orsmoking. The prevalence of each of these risk factors is
also high in the Scottish population. Additionally, Scotland’s
overall health is comparatively poor for a Western county,
particularly amongst people of working age. This includes
heart disease.
Statins, also known as 3-hydroxy-3-methylglutaryl co-
enzyme A (HMG-CoA) reductase inhibitors, were first
prescribed in Scotland in 1989. They have revolutionised
the treatment of hypercholesterolaemia [2], by lowering
serum cholesterol and reducing cardiac morbidity and
mortality in both primary and secondary prevention of
coronary artery disease [2,3]. There has been a consis-
tent increase in prescribing of statins, which reflects the
increase in prescribing of drugs for cardiovascular dis-
ease (Additional file 1: Supplementary material 1).
Their beneficial effects are usually attributed to their
capacity to reduce endogenous cholesterol synthesis
[4,5]. They competitively inhibit HMG-CoA reductase,
the major rate-limiting enzyme that controls the conver-
sion of HMG-CoA to mevalonic acid (MA) [6,7]. Thesetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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localisation and function of many proteins involved in
important intracellular signalling pathways (e.g. Ras and
Rho proteins) [6,7]. Therefore, besides lowering choles-
terol levels, statins exert effects on many essential cellu-
lar functions including cell proliferation, differentiation,
and survival as well as participating in the regulation of
cell shape and motility [8]. It is these other effects of
MA and the fact that many malignant cells present an
increased HMG-CoA reductase activity, which suggest
that selective inhibition of the HMG-CoA reductase en-
zyme could lead to a new chemotherapy for cancer dis-
ease [9].
Results obtained in vitro have demonstrated that sta-
tins possess a number of anti-tumour effects and
through a variety of potential mechanisms (Additional
file 1: Supplementary material 2). In vivo studies have, in
the main, endorsed in vitro results by the display of anti-
tumour effects in numerous animal tumour models
resulting in retardation of tumour growth; inhibition of
angiogenesis and/or inhibition of the metastatic process
[10-15]. Additionally a number of studies have legiti-
mised the potential of statins to significantly increase
the chemopreventive efficacy of other anti-tumour treat-
ments at doses much lower that are needed for their
anti-proliferative effects [16-21].
Epidemiological studies have in the main concentrated
on the association with risk of colorectal cancer. Results
of these have been inconsistent (Additional file 1: Sup-
plementary material 3 and 4) and the exact role of sta-
tins remains to be elucidated. More recently there has
been a growing interest in the association of statins with
disease progression and survival. The former has been
explored in only two studies [22,23] and the latter in
one [23]. Findings from these indicated that long term
use of statins may be associated with a less advanced
tumour stage and a better survival rate [22,23].
The objective, addressed by this study, was to explore
the association between statin use and colorectal cancer
risk, progression and survival in a Scottish population.
To date no study has investigated these associations of
statin use and CRC in a Scottish population and data
otherwise remains inconclusive.
Methods
Ethics statement
Ethical approval was obtained from the Multi Centre Re-
search Ethics committee for Scotland (MREC) and rele-
vant Local Research Ethics committees. All participants
provided written informed consent.
Study population
The study population comprised a subpopulation of
cases and controls resident in Tayside (309 cases and294 controls) who were involved in the Scottish Study of
Colorectal Cancer (SOCCS; original sample size: 3,455
cases and 3,396 controls).
SOCCS study
The aim of the SOCCS study was to investigate the
genetic, diet and lifestyle factors which influence
colorectal carcinogenesis. Incident cases of adeno-
carcinoma of the colon or rectum in patients aged
16–79 presenting to surgical units in Scottish hospi-
tals between 1999 and 2006 were prospectively
recruited into the SOCCS study. Research staff were
based in each of the main surgical centres throughout
Scotland. This minimised ascertainment bias and
assured recruitment within four weeks of admission
thus limiting survival bias due to rapid attrition of
cancer-related deaths. Those not approached were:
patients who died before ascertainment; patients too
ill to participate; patients with a recurrence of CRC
or patients who were unable to give informed con-
sent. 32% of all ascertained incident cases of CRC
were recruited to participate in SOCCS. Matched con-
trols (on age (±1 year), sex and region of residence)
were identified at random from a population-based
register (community health index) and invited via
their general practitioner to participate. Participation
rates among those approached were approximately
52% for cases and 39% for controls. Both the food
frequency questionnaire and the lifestyle and cancer
questionnaire had to be completed to a sufficiently high
level for analysis to be valid. Thus valid analysis was only
possible for 68% of recruited cases and 88% of recruited
controls (see Theodoratou E et al., 2007 [24] for further
recruitment details). For the purposes of this particular
study data linkage was only feasible for those resident in
Tayside, Scotland and this further reduced the total sam-
ple size. (See Additional file 1: Supplementary material 5
for flow sheet).
Lifestyle and dietary data
Subjects completed one questionnaire about their gen-
eral lifestyle and one semi-quantitative food frequency
questionnaire (Scottish Collaborative Group FFQ, Ver-
sion 6.41; http://www.foodfrequency.org). The main
characteristics of these questionnaires and data on
FFQ validity have been previously described [24-26].
Survival analysis data
Up to the censoring date (31/08/2009), there were
106 deaths in the 309 cases that were included in the
current analysis. Cause of death was determined by
examining all death certificates in a blinded manner
with respect to statin use. Ninety-one of the 106
deaths were due to CRC (84% of all deaths). Each
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Joint Committee on Cancer (AJCC) stage derived
from a synthesis of clinical, pathological and imaging
information (Additional file 1: Supplementary material
6). Staging involved contact with individual patient
general practitioners and surgeons, radiology and
pathology departments, as well as each of the mana-
ged clinical networks throughout Scotland.Statin data
Dispensed prescription data (medication, quantity, the
pharmacy and the prescriber) is routinely collected for
the purposes of fee payment to pharmacies. The
Health Informatics Centre (HIC) in Dundee, Tayside
has reliably collected these data together with the
CHI (Community Health Index) numbers from all
Tayside community dispensed prescriptions. CHI is a
population register, which is used in Scotland for
healthcare purposes. The CHI number uniquely iden-
tifies a person on the index.
Data linkage was undertaken with the assistance of the
HIC, which provided the CHI numbers and statin data,
and the Information Statistics Division of National Services
(ISD) which provided the CHI numbers for all our study
participants (Additional file 1: Supplementary material 7).
Statin use was described using four different vari-
ables: one or more prescriptions dispensed at least two
months pre-recruitment; one or more prescriptions
dispensed at least seven months pre-recruitment; two
or more prescriptions dispensed at least two months
pre-recruitment; and two or more prescriptions dis-
pensed at least seven months pre-recruitment. In the
survival analysis statin use was explored as one or
more prescriptions dispensed pre-diagnosis, two or
more prescriptions dispensed pre-diagnosis and simi-
larly for post-diagnosis.
These variables were chosen for two reasons. Firstly,
by looking at those who had at least one statin pre-
scription dispensed we can investigate the total group
of statin users. However they may not have taken the
tablets from that first prescription and may not have
returned for a further prescription. Thus by looking
at those who were dispensed two or more prescrip-
tions there is greater likelihood that the medication
was indeed used. Secondly, according to the hypothe-
sized underlying biologic mechanism, a minimum ex-
posure period is required for statins to have any
effect on the development of cancer. Therefore, statin
use was described in two ways, two months pre-
recruitment and seven months pre-recruitment. The
latter allowed a threshold of at least six months even
accounting for the maximal period of time from diag-
nosis to recruitment in the case of CRC patients.Statistical analysis
Data were analysed using SPSS version 14.0 and 19.0
(SPSS Inc. Chicago, IL) and STATA version 10.1 (Stata
corp, college station, Texas).
The frequencies and distribution of each variable were
checked. Any variable with a skewed distribution was
normalised by log transformation. The Pearson χ2 test
and the t-test were used to test the difference between
cases and controls in terms of categorical and continu-
ous lifestyle and demographic variables. Characteristics
of control statin users (≥1 prescription dispensed at least
two months pre-recruitment) and control non-users
were compared in an identical manner to above.
Endpoints investigated were differences in risk (inci-
dence) of colorectal cancer between statin users and
non-users, and differences in staging and in mortality
from colorectal cancer between statin users and non-
users.
Conditional logistic regression models were used in
risk analysis and Cox’s hazard models were used for sur-
vival in estimating the strength of the association be-
tween CRC and statin use for each of the statin
categories. Logrank tests and Cox’s hazard models
(crude and adjusted for stage of cancer, age and sex)
estimated statin effects on all-cause and CRC-specific
mortality. For each statin category the model was
adjusted for matching factors (age +/−1 year, sex and re-
gion of residence); family history of CRC (low and
medium/high); past medical history of cancer, past med-
ical history of bowel disease (including irritable bowel
syndrome), body mass index (BMI) (kg/m2 continu-
ously), smoking (3 categories – current, former and
never), physical activity (hours of cycling/sport per week)
and regular NSAID intake (yes versus no).
Results
SOCCS study participation
52% of colorectal cancer cases, and 39% of controls,
approached agreed to participate. Analysis of those who
participated to those who did not found that the two
groups were statistically significantly different for age,
sex and health board area of residence and deprivation
score (Additional file 1: Supplementary material 8–11).
SOCCS study and statin use
Over 99% of the 309 cases and 294 controls studied were
Caucasian, 53% were male and 50% were 63 years old or
older.
There were no significant differences between cases
and controls in terms of age, sex, smoking status, phys-
ical activity, alcohol intake, energy intake, deprivation
category, past medical history of bowel disease, regular
use of NSAIDs and hormone replacement therapy or
hormonal contraception (among women) (Table 1).
Table 1 Demographic characteristics and lifestyle factors
of the study population
Variables Cases
(n = 309)*
Controls
(n = 294)*
P-value †
Age at recruitment 60.0 (11.8) 61.4 (13.96) 0.19
Sex:
Men 160 (51.8) 161 (54.8)
Women 149 (48.2) 133 (45.2) 0.46
FH risk***:
Low 226 (78.7) 265 (99.6)
Medium/High 61 (21.3) 1 (0.4) <0.001
Smoking status:
Never 103 (33.3) 90 (30.6)
Former 87 (28.2) 115 (39.4)
Current 41 (13.3) 45 (15.3) 0.18
Not known 78 (25.2) 44 (15.0)
Physical activity (cycling & other sport in hours/week) ‡
0 125 (56.6) 128 (53.6)
0.1-3.5 56 (25.3) 65 (27.2)
3.6-7 23 (10.4) 24 (10.0)
>7 17 (7.7) 22 (9.2) 0.48
BMI‡ ¥:
<25 92 (29.8) 80 (27.2)
25-29.9 102 (33.0) 105 (35.7)
≥30 36 (11.7) 64 (21.8) 0.02
Unknown 79 (25.6) 45 (15.3)
Alcohol intake (g/day)‡ 12.7 (14.6) 12.9 (13.9) 0.76
Energy intake (kJ/day)‡ 11016 (3896) 11054 (4572) 0.80
DEPCAT††
1 33 (10.7) 33 (11.2)
2 76 (24.6) 66 (22.4)
3 78 (25.2) 79 (26.9)
4 69 (22.3) 66 (22.4)
5 24 (7.8) 22 (7.5)
6 27 (8.7) 27 (9.2)
7 2 (0.6) 1 (0.3) 0.99
PMH Bowel disease (incl. IBS) 18 (7.8) 23 (9.3) 0.56
PMH Cancer ± 24 (10.3) 13 (5.1) 0.03
Statin use: at least 1 25 (8.1) 44 (15.0) <0.01
prescription dispensed 2/12 Male: 18 Male: 31 Male: <0.05
pre-recruitment Female: 7 Female: 13 Female:0.10
Statin use: at least 24 (7.8) 38 (12.9) 0.04
1prescription dispensed
7/12
Male: 17 Male: 28 Male: 0.08
pre-recruitment Female: 7 Female: 10 Female: 0.32
Statin use: 2+ prescriptions 24 (7.8) 38 (12.9) 0.04
Table 1 Demographic characteristics and lifestyle factors
of the study population (Continued)
dispensed. First being
at least
Male: 17 Male: 27 Male: 0.11
2/12 pre-recruitment Female: 7 Female: 11 Female: 0.22
Statin use: 2+ prescriptions 23 (7.4) 34 (11.6) 0.084
dispensed. First
prescription at
Male: 16 Male: 25 Male: 0.14
least 7/12 pre-recruitement Female: 7 Female: 9 Female: 0.45
Regular use of NSAIDs**:
Yes 53 (69.7) 87 (70.7)
No 165 (17.1) 146 (17.9) 0.003
Not known 91 (13.1) 61 (11.4)
HRT use:
Yes 30 (28.0) 40 (37.0)
No 76 (71.0) 68 (63.0) 0.17
Not known 1 (0.9) 0 (0)
Hormonal contraception use:
Yes 36 (33.6) 40 (37.0)
No 70 (65.4) 67 (62.0) 0.60
Not known 1 (0.9) 1 (0.9)
* Mean values and in parenthese standard deviations for quantitative
variables; number of subjects and in parentheses percentages for categorical
variables.
† P-values from the Pearson χ2 for categorical variables; from t-test for
continuous variables. All statistical tests were 2-sided.
‡ P-values were computed from the natural logarithmic transformed variables.
** Regular use = at least four times a week for at least one month.
†† DEPCAT (Carstairs deprivation index) based on the 2001 Census data; 7
categories ranging from very low deprivation (DEPCAT 1) to very high
deprivation (DEPCAT 7).
¥ In calculating the BMI the weight and height used were from 1 year before
diagnosis for cases and one year before recruitment for controls.
± Information on past cancers was self-reported by patients via the lifestyle
questionnaire. The question that was asked was: “up until a year ago had you
ever been given a diagnosis of cancer?”. Type and staging were not requested.
*** Family history risk was assigned according to the Scottish guidelines:
According to the Scottish Executive cancer guidelines (http://www.sehd.scot.
nhs.uk/), the criteria for high family history risk of colorectal cancer are: 1) at
least three family members affected by colorectal cancer or at least two with
colorectal cancer and one with endometrial cancer in at least two generations;
one affected relative must be ≤50 years old at diagnosis and one of the
relatives must be a first degree relative of the other two; or 2) presence of the
HNPCC syndrome; or 3) untested first degree relatives of known gene carriers.
The criteria for moderate risk are: 1) one first degree relative affected by
colorectal cancer when aged <45 years old; or 2) two affected first degree
relatives with one aged <55 years old; or 3) three affected relatives with
colorectal or endometrial cancer, who are first degree relatives of each other
and one a first degree relative of the consultant. Individuals that do not fulfil
all the above criteria are classified as low family history risk (Scottish Executive
cancer guidelines).
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CI 1.27, 12.5; p-value = 0.02). Cases were also signifi-
cantly more likely to have a personal history of cancer
(OR 2.13; 95%CI 1.05, 4.17; P-value = 0.03) and/or a
family history of CRC (OR 71.6; 95% CI 9.84, 520.1;
P-value < 0.001) (Table 1).
Age, sex and BMI were statistically significantly different
between statin users, (those who had dispensed at least one
Lakha et al. BMC Cancer 2012, 12:487 Page 5 of 10
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users (Additional file 1: Supplementary material 12). When
men and women were explored separately there were no
significant differences between users and non-users in
women (Additional file 1: Supplementary material 13).
However in men there was a small but significant difference
in age between statin users and non-users (Additional file 1:
Supplementary material 14). Use of sigmoidoscopy and/or
colonoscopy was explored and no association was found
between statin users and non users amongst anyof the dif-
ferent statin groups when missing data were excluded
(Additional file 1: Supplementary material 15).
Statins and risk of colorectal cancer
Table 2 presents the results of the logistic regression
models looking at the relationship between CRC and
each of the four variables of statin use. Statin use was
associated with a statistically significantly reduced risk of
CRC for one of the four variables in the unadjusted
model; OR = 0.52 95% CI = 0.31, 0.89 for those who had
at least one prescription dispensed at least two months
pre-recruitment (Table 2). However after adjusting for
confounding factors, the association was significant for
three variables; OR = 0.33 95% CI 0.15, 0.69 for those
who had at least one prescription dispensed at least two
months pre-recruitment; OR = 0.39 95% CI 0.18, 0.85 for
those who had at least one prescription dispensed seven
months pre-recruitment and OR = 0.42 95%CI 0.19, 0.92
for those who had at least two prescriptions dispensed
the first being at least two months pre-recruitment.
For the logistic regression the sample size was 405 (194
cases of colorectal cancer and 211 controls) due to there
being at least one piece of missing data for 198 study
participants.Table 2 Association between colorectal cancer and statin use
model) and 190 cases and 209 control patients in the adjuste
Statin use Unadjusted model
Cases (309) Controls (294) Basic O
P-value
No use of statins 284 250 1.0 (refe
≥1dispensed prescription
at least 2 months pre-recruitment
25 44 0.52 (0.
0.016 *
≥1dispensed prescription
at least 7 months pre-recruitment
24 38 0.60 (0.
0.067
≥2 dispensed prescriptions
at least 2 months pre-recruitment
24 38 0.60 (0.
0.064
≥2 dispensed prescriptions
at least 7 months pre-recruitment
23 34 0.65 (0.
0.135
* Adjusted for matching factors (age +/−1 year), sex and region of residence). OR =
† Adjusted for matching factors ((age +/−1 year), sex and region of residence), Fam
bowel disease, BMI, smoking, physical activity and regular NSAID intake.
** statistically significant at p < 0.05.The analysis was repeated including only those with
complete data for each of the potential confounders
(PMH Cancer, FH of Cancer, PMH IBD, BMI, smoking
history, regular NSAID use and physical activity). This
reduced the sample size to 405 (194 cases of colorectal
cancer and 211 controls). The results were found to be
significant for three of the four statin variables in both
the unadjusted and adjusted models (Additional file 1:
Supplementary material 16).Statins, survival and death from colorectal cancer
There were 106 deaths within the group of 309 cases of colo-
rectal cancer. The only significant difference between those
deceased and alive was in physical activity (p value 0.008)
(Table 3). There was no association found between stage of
colorectal cancer at diagnosis and statin use (Additional file
1: Supplementary material 17). Statin use was found to be
negatively associated with all-cause mortality and CRC-
specific mortality when two or more prescriptions of statin
had been dispensed post diagnosis (p-value 0.05 and 0.03; re-
spectively). However, post adjustment for confounding fac-
tors this association was no longer significant. None of the
other drug categories were found to be associated with either
all-cause mortality or colorectal cancer in the unadjusted
analysis, when adjusted for AJCC alone and in multivariable
analysis (adjusted for age, sex and AJCC) (Table 4). Similarly
when physical activity was included in factors adjusted for
both alone and in multivariable analysis no association was
either all-cause or CRC-specific mortality (data not shown).
When only complete data were used then the results
were significant for three of the four drug categories both
in the unadjusted and adjusted analysis (Additional file 1:
Supplementary material 16).among 309 cases and 294 control patients (unadjusted
d model
Adjusted model
R* (95% CI) Cases (194) Controls (211) Adjusted OR† (95% CI)
P-value
rent) 154 145 1.0 (referent)
31, 0.89) 15 38 0.33 (0.15, 0.69)
* 0.004**
35, 1.04) 14 32 0.39 (0.18, 0.85)
0.017**
35, 1.03) 14 32 0.42 (0.19, 0.92)
0.030**
37, 1.14) 13 28 0.49 (0.22, 1.08)
0.077
Odds ratio; CI = confidence interval.
ily history of cancer, past medical history of cancer, past medical history of
Table 3 Demographic characteristics and lifestyle factors
of cases (survival analysis)
Variables Deceased
(n = 106)*
Alive
(n = 202)*
P-value
Age at recruitment 60.4 (12.18) 59.8 (11.66) 0.66
Sex:
Men 56 (52.8) 103 (51.0)
Women 50 (47.2) 99 (49.0) 0.76
FH risk:
Low 78 (82.1) 148 (77.1)
Medium/High 17 (17.9) 44 (22.9) 0.33
Smoking status:
Never 31 (48.4) 71 (42.8)
Former 20 (31.3) 67 (40.4)
Current 13 (20.3) 28 (16.9) 0.44
Physical activity (cycling & other sport in hours/week) ‡
0 37 (62.7) 88 (54.3)
0-3.5 6 (10.2) 50 (30.9)
3.5-7 6 (10.2) 11 (6.8)
>7 10 (17.0) 13 (8.0) 0.008
BMI‡:
<25 24 (36.4) 68 (41.7)
25-29.9 31 (47.0) 71 (43.6)
≥30 11 (16.7) 24 (14.7) 0.75
Alcohol intake (g/day)‡ 13.1 12.6 0.29
(16.0) (14.2)
Energy intake (kJ/day)‡ 11222.2 10939.5 0.54
(3886.9) (3909.0)
DEPCAT††
1 11 (10.4) 22 (10.9)
2 23 (21.7) 53 (26.2)
3 25 (23.6) 52 (25.7)
4 29 (27.4) 40 (19.8)
5 9 (8.5) 15 (7.4)
6 9 (8.5) 18 (8.9)
7 0 (0) 2 (1.0) 0.72
PMH Bowel disease
(incl. IBS)
6 (9.1) 12 (7.3) 0.65
PMH Cancer 6 (9.1) 17 (10.3) 0.78
Statin use: at least 1
prescription dispensed
2/12 pre-recruitment
8 (7.6) 16 (7.9) 0.91
Statin use: at least 1
prescription dispensed
7/12 pre-recruitment
8 (7.6) 15 (7.4) 0.97
Statin use: 2+
prescriptions dispensed.
First being at least
2/12 pre-recruitment
8 (7.6) 15 (7.4) 0.97
Table 3 Demographic characteristics and lifestyle factors
of cases (survival analysis) (Continued)
Statin use: 2+
prescriptions dispensed.
First prescription at least
7/12 pre-recruitement
8 (7.6) 14 (6.9) 0.84
Regular use of NSAIDs**:
Yes 47 (73.4) 127 (78.4)
No 17 (26.6) 35 (21.6) 0.43
HRT use:
Yes 7 (26.9) 23 (28.8)
No 19 (73.1) 57 (71.3) 0.86
Hormonal contraception use:
Yes 6 (23.1) 30 (37.5)
No 20 (76.9) 50 (62.5) 0.18
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Statins and risk of colorectal cancer
In the univariable analysis of risk a statistically significant
protective association between CRC risk and one of the
four statin variables was observed. However, after control-
ling for several potential confounders the association with
three of the four statin variables (all but having two or
more prescriptions with the first at least seven months
pre-recruitment) was statistically significant (Table 1).
However the sample size decreased significantly when lo-
gistic regression was carried out for the adjusted model
and this was reflected in the wide confidence intervals.
Thus the results must be treated with caution and larger
studies need to be conducted to confirm these findings.
The association between use of statins and colorectal
cancer risk has been explored via epidemiological ana-
lyses. Whilst the results from some of these studies have
supported the hypothesis that statin use may reduce risk
of colorectal cancer (Additional file 1: Supplementary
material 2, 3), several recent meta-analyses have con-
cluded that there is no association (Additional file 1:
Supplementary material 18 and 19). This may not neces-
sarily be the case for a number of reasons. Whilst meta-
analysis does provide an explicit systematic approach, in
this situation it still has limited sensitivity for detecting
carcinogenic potential at a specific cancer site. With re-
spect to the studies included, RCT’s exploring statin use
have not been designed to evaluate statins as preventive
agents of cancer thus being insufficiently powered,
follow-up has been relatively short and external validity,
with regard to cancer risk in a post-marketing popula-
tion of statin users, is questionable as the patients in the
trials have been from highly selected groups. Observa-
tional studies have also been limited by insufficient num-
bers, multiple biases including potential misclassification
bias and incomplete control of confounding. Hence
overall the results remain inconclusive.
Table 4 Survival analysis for all cause and colorectal cancer mortality by statin intake
All cause mortality No of
events
Persons
at risk
Log rank
test
Unadjusted Analysis Adjusted for AJCC Multivariable adjusted analysis
HR 95% CI HR 95% CI HR 95%CI
Statin use: at least 1 prescription
No 91 251 1.00 1.00 1.00
Yes 15 57 0.11 0.64 0.37, 1.10 0.65 0.37, 1.15 0.58 0.33, 1.03
P = 0.11 P = 0.14 P = 0.07
Statin use: at least 1 prescription dispensed before recruitment
No 91 251 1.00 1.00 1.00
Yes 8 26 0.62 0.83 0.40, 1.71 0.76 0.32, 1.38 0.59 0.28, 1.24
P = 0.62 P = 0.28 P = 0.16
Statin use: at least 1 prescription dispensed after recruitment
No 91 251 1.00 1.00 1.00
Yes 7 31 0.08 0.51 0.23, 1.09 0.67 0.29, 1.54 0.61 0.26, 1.41
P = 0.08 P = 0.34 P = 0.24
Statin use: 2+ prescription
No 94 259 1.00 1.00 1.00
Yes 12 49 0.09 0.59 0.33, 1.08 0.63 0.34, 1.15 0.57 0.31, 1.05
P = 0.09 P = 0.13 P = 0.07
Statin use: 2+ prescription dispensed before recruitment
No 94 259 1.00 1.00 1.00
Yes 8 25 0.70 0.87 0.42, 1.79 0.70 0.34, 1.45 0.64 0.31, 1.34
P = 0.70 P = 0.34 P = 0.24
Statin use: 2+ prescription dispensed after recruitment
No 94 259 1.00 1.00 1.00
Yes 4 24 0.04 0.36 0.13, 0.99 0.54 0.20, 1.49 0.49 0.18, 1.36
P = 0.05 P = 0.24 P = 0.17
Colorectal cancer mortality HR 95% CI HR 95% CI HR 95%CI
Statin use: at least 1 prescription
No 79 251 1.00 1.00 1.00
Yes 12 57 0.09 0.60 0.32, 1.09 0.61 0.32, 1.15 0.56 0.29, 1.07
P = 0.09 P = 0.13 P = 0.08
Statin use: at least 1 prescription dispensed before diagnosis
No 79 251 1.00 1.00 1.00
Yes 7 26 0.66 0.84 0.39, 1.82 0.65 0.30, 1.42 0.60 0.327, 1.32
P = 0.66 P = 0.28 P = 0.20
Statin use: at least 1 prescription dispensed after
No 79 251 1.00 1.00 1.00
Yes 5 31 0.05 0.42 0.17, 1.05 0.58 0.21, 1.60 0.54 0.19, 1.50
P = 0.06 P = 0.29 P = 0.24
Statin use: 2+ prescription
No 82 259 1.00 1.00 1.00
Yes 9 49 0.06 0.52 0.26, 1.03 0.56 0.28, 1.11 0.51 0.25, 1.03
P = 0.06 P = 0.10 P = 0.06
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Table 4 Survival analysis for all cause and colorectal cancer mortality by statin intake (Continued)
Statin use: 2+ prescription dispensed before recruitment
No 82 259 1.00 1.00 1.00
Yes 7 25 0.73 0.87 0.40, 1.88 0.67 0.31, 1.48 0.64 0.26, 1.40
P = 0.73 P = 0.33 P = 0.26
Statin use: 2+ prescription dispensed after recruitment
No 82 259 1.00 1.00 1.00
Yes 2 24 0.02 0.21 0.05, 0.86 0.35 0.09, 1.45 0.33 0.08, 1.35
P = 0.03 P = 0.15 P = 0.12
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Survival analysis did detect an effect on all-cause mortal-
ity and CRC-specific mortality in the unadjusted model
but did not after adjustment for confounding factors. A
post hoc power calculation (Additional file 1: Supple-
mentary material 20) showed that we didn’t have enough
power to detect a small survival effect and therefore lar-
ger studies are required.
Increasingly the interest in the association between
statin use and CRC has been with regard to stage at
presentation and survival rate [27]. We found neither a
positive nor a negative association with either in our
study. To our knowledge only two studies have explored
this previously [22,23]. A case–control study by Siddiqui
et al. [23] et al. explored, how use of statins might influ-
ence presentation of colorectal cancer and survival rate
and found that long-term use of statins is associated
with a less advanced tumour stage, a higher prevalence
of right-sided tumours, a lower frequency of distant me-
tastases, and a better five-year survival rate. This study
had a larger sample size than ours. Similarly to the
current study, it used a pathology database to identify
patients with colorectal cancer thus minimising selection
bias. Medical histories were obtained from medical
records and did not rely on self-recall thus minimizing
recall bias though limiting the data that could be col-
lected and increasing the likelihood of incomplete con-
trol of confounding. Statin use was from dispensing data
via a pharmacy database, similarly to the current study,
thus raising the possibility of misclassification bias.
The second study was a population-based case–
control study by Coogan et al. [22]. As part of their ex-
ploratory analysis they looked at stage at presentation
and found an association between statin use and reduced
risk of stage IV cancer at presentation. A strength of this
study was that it specifically looked at the association
between statin-use with colorectal cancer. It was also the
first study where specific attention was paid to statin
type, dose and duration of use and where the potentially
confounding or synergistic effects of non-steroidal anti-
inflammatory drug (NSAID) use were investigated. How-
ever, there were several limitations as acknowledged bythe authors. There may have been selection bias as par-
ticipation was voluntary and in the instance of cases
physician permission was required before the patient
could be approached. However, the associations of CRC
with NSAID use, oral contraceptive use and with screen-
ing were in the expected direction and thus provided re-
assurance as to the validity of the data. Recall bias was
another potential limitation, since exposure was classi-
fied solely on the basis of self-reported drug use with no
verification. Accuracy of recall is a known problem in
these situations. Similarly to the study by Poynter et al.
[28] there was a likelihood of detection bias. A further
limitation, as with every observational study, was that of
potentially incomplete control of confounding though
many efforts were made to control for many potential
confounders.
Strengths and limitations
Our study has several strengths. Firstly active case re-
cruitment within each of the surgical centres throughout
Scotland, within 1–3 months of diagnosis, limited both
ascertainment and survival bias. Secondly recall bias was
minimised by using computerised databases to link dis-
pensed statins to study participants. Thirdly, misclassifi-
cation bias was minimised by looking at those who had
been dispensed at least two prescriptions of statin thus
increasing the likelihood of compliance even though
drug use was reliant on dispensing data. And fourthly,
overestimation was reduced by using a number of statin
variables, similarly to Kaye and Jick [29] and Graaf et al.
[30], of which two included a six month latent period
(plus one month allowance for recruitment.
The main limitation in this study was the lack of avail-
ability of prescription data for use in epidemiological re-
search and the reason for the small sample size. Other
limitations include that data regarding statin use were
only obtainable for 309 cases and 294 controls due to
limited availability of data linkage. Also, data were only
available from 1996 which potentially may have led to
misclassification of some ex-statin users. With statin use
only being ascertained from 1996, this is likely to be too
short a time-scale as cancer is well known to have a long
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itionally, whilst efforts were made to reduce survival bias
by having research staff based at every surgical centre
throughout Scotland those patients who were too ill to
participate were excluded as were those who died before
ascertainment. Valid analysis of questionnaires, com-
pleted by those who consented to participate in the
SOCCS study, was only feasible for 68% of cases as com-
pared to 88% of controls. This lower completion rate in
cases, as mentioned earlier, is thought to be due to cases
being too unwell to fully cooperate and thus inadvert-
ently a further element of survival bias is present in the
study as subjects with missing data were excluded from
the logistic regression analysis. And there may have
been some selection bias since only 32% of incident
cases of colorectal cancer were approached. Of those
approached only 52% of cases and 39% of controls
agreed to participate. When participants were compared
to non-participants, for both cases and controls, with
respect to age, gender, health board area and
deprivation index we found there to be statistically sig-
nificant differences (Additional file 1: Supplementary
material x-y) confirming participation bias. We had very
limited data for nonparticipants and were therefore un-
able to do any further comparisons. Finally our sample
size was further reduced, due to missing data (Additional
file 1: Supplementary material 21), leaving us with
complete data for only 193 cases and 213 controls when
we undertook logistic regression (Additional file 1:
Supplementary material 16). This further reduced the
power of the study.
Given that the use of statins is rapidly increasing
worldwide, with more than 10% of the adult population,
and 25% of those over 60 years of age in the United
States, using statins [32], any association of statins with
increased or decreased survival, stage at presentation or
risk of colorectal cancer would have a substantial public
health impact. Many studies, both trials and observa-
tional have been undertaken to date, and it would appear
reasonable that rather than expend further resource in
repeating such studies, though on a larger scale, it is
time to consider exploring a new direction in trying to
ascertain if there is a causal link between statin use and
CRC. We believe the most plausible option at present is
to undertake a meta-analysis of randomised control
trials. As mentioned earlier, to date, there have been four
meta-analyses of RCTs exploring the colorectal cancer
statin link. The latest was in 2007 and whilst there have
been numerous RCTs involving statins only six have
published their findings with respect to the association
with CRC. Possibly by contacting the investigators of
each of the RCTs involving statin use it might be pos-
sible to ascertain if there is any data available on inci-
dence and mortality of CRC thus allowing both power tobe increased as well as exploration of incidence, survival,
dose–response, the effects of type and possibly duration
of use also.
In conclusion, collective evidence remains inconclusive
that statins are protective against colorectal cancer.
Whilst laboratory data suggest the biological plausibility
of an anti-cancer effect of statins against colorectal can-
cer, epidemiological data, both when viewed as individ-
ual studies and in meta-analyses are inconsistent and
not supportive of an impact on risk.
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